• Efficacy assessed by swelling, redness, presence of pus, hardening of the skin, necrotic tissue, purulent drainage, tenderness, and ulceration at baseline, day 7 and day 14
• Efficacy assessed as success (Test of Cure) after 4,7, 10 and 14 days of treatment with daptomycin on infecting Gram positive bacteria
• Efficacy assessed as percentage of patients with clinical success (TOC) at day 4 and 10
• Efficacy assessed by duration of treatment with daptomycin
• Efficacy assessed by time of resolution of infection
• Safety assessed by hematological and biochemical tests, urinalysis, and recording and follow-up of emerging AE and SAE.

This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults

Inclusion criteria:

• Subjects with a diagnosis of complicated skin and skin-structure infections cSSTI) defined as infection normally requiring surgical/local debridement of sufficient severity to warrant hospitalisation and intra venous antimicrobial treatment
• Infection to be due to Gram-positive bacteria
• Hospitalised subjects
• Written informed consent
• Female patients of childbearing potential must have a negative pregnancy test urine or serum) at baseline and must use effective contraception throughout the study period.

Exclusion criteria:

• Complicated skin and skin-structure infections of the following categories:
• Infected burns
• Severely impaired arterial blood supply
• Decubitus ulcers
• Infected diabetic foot ulcers associated with osteomyelitis
• Infected human or animal bites
• Perirectal abscess
• Necrotising fasciitis or gangrene
• Infections expected to require more than 14 days of intravenous antimicrobial therapy
• Skin and/or skin structure infection that can be treated by surgery alone
• Infections associated with a permanent prosthetic device that will not be removed within 2 days of study enrollment
• Uncomplicated skin or soft tissue infection
• Documented bacteremia at baseline
• Concomitant infection nearby the site of infection at baseline, potentially interfering with the evaluations
• Hospitalization for conditions related to rabdomyolysis
• HIV with CD < 200 or < 14%
• Immune function alterations
• Lack of sufficient purulent material for colture and Gram test
• Systemic or local antibiotic administration with known anti-Gram positive activity in the preceding 48 hours
• cSSTI known or believed to be related to fungal, parasitic or viral infection
• Pneumonia
• Local or systemic known or suspected allergy to daptomycin
• Creatinine clearance < 30mL/min
• Severe liver damage (Child-Pugh class C) or ALT and/or AST > 3 x ULN and/or bilirubin > 1.5 x ULN
• Use of any experimental drugs in the preceding 30 days
• Severe medical conditions that in the investigator's opinion could counter indicate participation in the study